Publications by authors named "Lisa Gauger"
Article Synopsis
- The study aimed to evaluate whether increasing urate levels through inosine treatment can slow down the progression of early Parkinson's disease, using data that suggests urate elevation might be beneficial.* -
- Conducted as a phase 3 trial, 298 participants with early-stage Parkinson's disease were randomly assigned to receive either inosine to elevate serum urate levels or a placebo, over a period of up to 2 years.* -
- Results from the study indicated no significant differences in clinical progression rates between the inosine and placebo groups, leading to an early closure of the trial based on an interim analysis.*
Objective: To determine whether providing remote neurologic care into the homes of people with Parkinson disease (PD) is feasible, beneficial, and valuable.
Methods: In a 1-year randomized controlled trial, we compared usual care to usual care supplemented by 4 virtual visits via video conferencing from a remote specialist into patients' homes. Primary outcome measures were feasibility, as measured by the proportion who completed at least one virtual visit and the proportion of virtual visits completed on time; and efficacy, as measured by the change in the Parkinson's Disease Questionnaire-39, a quality of life scale.
Background: Parkinson's disease (PD) is among the most prevalent neurodegenerative conditions. While motor and non-motor aspects of this disease have been well characterized, no objective biomarker exists to support an accurate clinical diagnosis. However, newer imaging techniques, including [123I]-FP-CIT (DaTSCAN), have demonstrated utility in differentiating between PD and non-neurodegenerative tremor disorders.
View Article and Find Full Text PDFBackground: Delivering specialty care remotely directly into people's homes can enhance access for and improve the healthcare of individuals with chronic conditions. However, evidence supporting this approach is limited.
Materials And Methods: Connect.
The objective of this study was to examine a remote method for maintaining long-term contact with Parkinson's disease (PD) patients participating in clinical studies. Long-term follow-up of PD patients is needed to fill critical information gaps on progression, biomarkers, and treatment. Prospective in-person assessment can be costly and may be impossible for some patients.
View Article and Find Full Text PDFArticle Synopsis
- This study examined the potential of using inosine, a urate precursor, to safely elevate serum urate levels in early Parkinson’s disease (PD) as a way to potentially slow down the progression of disability associated with the disease.
- Conducted from 2009 to 2011, the SURE-PD trial involved 75 participants who were either given inosine or a placebo in a controlled environment, with a focus on monitoring safety, tolerability, and urate elevation over a median follow-up of 18 months.
- Results showed that serious adverse events were either similar or lower in the inosine groups compared to placebo, with high tolerability reported; however, 3 participants experienced
We performed a placebo-controlled trial of CEP-1347, an inhibitor of neuronal apoptotic cell death, in patients with early Parkinson's disease (PD) to determine whether long-term therapy would slow disability progression. This also provided an opportunity to monitor cancer incidence in a large cohort of PD patients followed prospectively including periods before and after patients developed disability requiring dopaminergic therapy. This was a multicenter study of 806 patients with early PD, without disability requiring dopaminergic therapy, assigned randomly to placebo or one of three doses of CEP-1347.
View Article and Find Full Text PDFObjective: To determine whether concentration of serum urate, a purine metabolite and potent antioxidant that has been linked to a reduced risk of Parkinson disease (PD), predicts prognosis in PD.
Design: Prospective study.
Setting: The Parkinson Research Examination of CEP-1347 Trial (PRECEPT) study, which investigated the effects of a potential neuroprotectant on rates of PD progression, was conducted between April 2002 and August 2005 (average follow-up time 21.